---
title: "PEIJIA-B's revenue for the first half of the year was approximately 350-360 million yuan, a year-on-year increase of about 16.2%-19.5%"
description: "PEIJIA-B announced that its revenue for the first half of 2025 is expected to be approximately RMB 350 million to RMB 360 million, representing a year-on-year growth of about 16.2% to 19.5%. The reven"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/251834904.md"
published_at: "2025-08-06T12:11:02.000Z"
---

# PEIJIA-B's revenue for the first half of the year was approximately 350-360 million yuan, a year-on-year increase of about 16.2%-19.5%

> PEIJIA-B announced that its revenue for the first half of 2025 is expected to be approximately RMB 350 million to RMB 360 million, representing a year-on-year growth of about 16.2% to 19.5%. The revenue growth is mainly attributed to the expansion of its market share in China's TAVR market, the launch of high-end product offerings, and strong performance of key neurointerventional products. During the reporting period, the total number of TAVR implants exceeded 2,050, a year-on-year increase of approximately 18.8%

According to the Zhitong Finance APP, PEIJIA-B (09996) announced that the group's revenue for the first half of 2025 is expected to be approximately 350 million to 360 million yuan, representing a year-on-year growth of about 16.2% to 19.5%.

The announcement stated that the main drivers of revenue growth are as follows: the group's market share in the transcatheter aortic valve replacement (TAVR) market in China has further expanded, and the product portfolio has shifted towards newly launched high-end products; strong performance of key neuro-interventional products, such as increased market penetration of existing leading products like the DCwire® microcatheter, Tethys AS® thrombectomy catheter, and Fastunnel® delivery balloon catheter; and the successful launch of the newly approved YonFlow® blood flow-directed stent.

During the reporting period, the group's comprehensive TAVR portfolio (including TaurusOne®, TaurusElite®, and the newly launched TaurusMax®) expanded to over 70 new medical institutions, covering more than 720 medical institutions as of June 30, 2025. The total number of TAVR implants during the reporting period exceeded 2,050, representing a year-on-year growth of approximately 18.8%

### Related Stocks

- [09996.HK - PEIJIA-B](https://longbridge.com/en/quote/09996.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 沛嘉醫療申請歐盟批准其心臟植入物 | 沛嘉醫療申請歐盟心臟植入物批准 | [Link](https://longbridge.com/en/news/275249808.md) |
| 沛嘉醫療為 GeminiOne TEER 系統提交歐盟 MDR CE 認證註冊 | 沛嘉醫療有限公司已提交其 GeminiOne 經導管邊緣對邊緣修復系統的歐盟醫療器械法規 CE 標誌申請，旨在治療二尖瓣關閉不全。此次提交是與歐洲合作伙伴 HighLife SAS 共同進行的。該產品也正在中國進行監管審查，並已獲得美國 F | [Link](https://longbridge.com/en/news/275242474.md) |
| 國泰海通維持對深圳精鋒醫療有限公司 H 股（2675）的買入評級 | 國泰君安的分析師昨日對深圳精鋒醫療有限公司 H 類股票維持買入評級，並設定目標價為 73.20 港元。目前，市場對深圳精鋒醫療有限公司 H 類股票的分析師共識評級為持有 | [Link](https://longbridge.com/en/news/275997117.md) |
| 我快 65 歲了，住在國外。我是否應該不註冊 Medicare？ | 一位接近 65 歲的美國 expatriate 對於是否註冊 Medicare 感到不確定，因為它通常不覆蓋國外的醫療服務。文章建議註冊 Medicare A 部分是有益的，因為如果個人已經繳納過相關費用，這部分可能是免費的。然而，關於 B | [Link](https://longbridge.com/en/news/275985803.md) |
| 我快 65 歲了，住在國外。我是否應該不註冊 Medicare？ | 本文討論了即將年滿 65 歲的美國 expatriate 在申請 Medicare 時需要考慮的事項。強調了即使在國外居住，也必須註冊 Medicare A 部分以避免罰款，因為 Medicare 通常不覆蓋海外醫療。文中還強調了 Medi | [Link](https://longbridge.com/en/news/275933962.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.